目的 分析痰熱清注射液輔助治療重癥肺炎的耐藥菌感染率改善作用。方法 選取2018年1月-2020年9月淮南朝陽醫(yī)院收治的105例重癥肺炎患者作為研究對象，將患者按照治療方法分為對照組（n=51）和觀察組（n=54）。對照組給予對癥基礎(chǔ)治療，觀察組在對照組的基礎(chǔ)上靜脈滴注痰熱清注射液，10 mL加入到500 mL 5%葡萄糖注射液，1次/d。療程2周。觀察兩組患者的臨床療效，比較兩組患者的耐藥菌檢出類型及檢出率、耐藥病原菌總清除率。結(jié)果 治療后，觀察組患者總有效率為90.74%，顯著高于對照組的76.47%，差異具有統(tǒng)計學(xué)意義（P<0.05）。兩組患者檢出耐藥菌類型主要以銅綠假單胞菌、鮑曼不動桿菌、肺炎克雷伯菌、金黃色葡萄球菌4種菌株為主，對照組和觀察組檢出率分別為68.63%、42.59%，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后，觀察組耐藥病原菌總清除率為82.61%，顯著高于對照組54.81%，差異具有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 在重癥肺炎患者中多數(shù)患者為革蘭陰性菌耐藥菌感染，而在常規(guī)西醫(yī)對癥、抗菌治療基礎(chǔ)上加用痰熱清注射液能顯著提高臨床療效和耐藥病原菌總清除率，降低治療過程中患者耐藥菌檢出率，值得臨床推廣。

Objective To analyze the clinical efficacy of Tanreqing Injection on infection rate of drug-resistant bacteria in patients with severe pneumonia. Methods A total of 105 patients with severe pneumonia admitted to Huainan Chaoyang Hospital from January 2018 to September 2020 were selected as the research subjects, and the patients were divided into control group (n=51) and observation group (n=54) according to treatment methods. Patients in the control group was given symptomatic basic treatment, and the observation group were iv administered with Tanreqing Injection intravenously on the basis of the control group, 10 mL was added to 500 mL 5% Glucose injection, once daily. The treatment course was 2 weeks. The clinical efficacy of two groups was observed, and the detection types and detection rates of drug-resistant bacteria, and the total clearance rate of drug-resistant pathogens in two groups were compared. Results After treatment, the total effective rate of observation group was 90.74%, which was significantly higher than 76.47% of control group, and the difference was statistically significant (P<0.05). The types of drug-resistant bacteria detected in two groups were mainly pseudomonas aeruginosa, acinetobacter baumannii, klebsiella pneumonia, and staphylococcus aureus, and the detection rates of control group and observation group were 68.63% and 42.59%, respectively, with statistical significance (P<0.05). After treatment, the total clearance rate of drug-resistant pathogens in the observation group was 82.61%, significantly higher than 54.81% in the control group, with statistical significance (P<0.05). Conclusion The majority of patients with severe pneumonia are infected by Gram-negative bacteria resistant bacteria, while the addition of Tanreqing Injection on the basis of conventional western medicine symptomatic and antibacterial treatment can significantly improve the clinical efficacy and the total clearance rate of drug-resistant pathogens, and reduce the detection rate of drug-resistant bacteria in patients during treatment, which is worthy of clinical promotion.

R974